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A B S T R A C T
Background: Acutely decompensated chronic heart failure (ADHF) is considered a life-threatening event.
Despite contemporary treatment strategies of ADHF, frequent recurrent hospitalizations due to other
cardiovascular reasons after discharge of patients from hospital occur. The objective of the study was to
examine the prognostic value of circulating endothelial-derived apoptotic microparticles (EMPs) to
mononuclear progenitor cells (MPCs) ratio for post-discharge patients with clinical stabilization after
ischemic ADHF.
Methods: We consecutively enrolled 136 patients (62 male) with coronary artery disease (CAD)
admitted with a primary diagnosis of ADHF. All patients gave written informed consent for participation
in the study. At baseline, all enrolled patients were hemodynamically stable and they had New York
Heart Association (NYHA) III/IV classes of ischemic chronic heart failure (CHF). Observation period
started at discharge from the hospital and was up to 3 years. Flow cytometry analysis for quantifying the
number of EMPs and angiogenic MPCs was used.
Results: Calculated EMP to MPC ratios in survivor and dead patient cohort were 8.4 (95% CI = 7.6–9.2)
and 78.9 (95% CI = 53.0–116.6), respectively (p = 0.001). MPCs, EMPs, NYHA class, N-terminal pro-brain
natriuretic peptide (NT-proBNP) and increased NT-proBNP > 30% within 24–84 h of admission period
remained statistically signiﬁcant for all-cause mortality, CHF-related death, and CHF-related
rehospitalization, whereas left ventricular ejection fraction and high-sensitivity C-reactive protein
for all variables did not. We found that the addition of EPMs to MPCs ratio to the ABC model (NT-pro-BNP,
increased NT-pro-BNP > 30%) improved the relative integrated discrimination indices by 19.6% for all-
cause mortality, by 21.7% for CHF-related death, and by 19.5% for CHF-related rehospitalization.
Conclusion: We demonstrated that EMP to MPC ratio is considered an important indicator of an
imbalance between angiogenic and apoptotic responses with possible relation to cardiovascular
outcomes in post-discharge patients with clinical stabilization after ischemic ADHF.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Acutely decompensated chronic heart failure (ADHF) is consid-
ered a life-threatening event with a short-term in-hospital mortality
range of 4.5–8.5% [1]. Despite contemporary treatment strategies for
ADHF, frequent recurrent hospitalizations due to other cardiovascu-
lar reasons after discharge from hospital occur [2]. Recent
investigations have shown that both neurohormonal and low-
intensity proinﬂammatory activation play pivotal roles in cardiovas-
cular remodeling, which leads to worsening of chronic heart failure
(CHF) [3]. Therefore, there are exacerbating factors for advanced CHF reserved.
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infections, non-compliance with low-salt diet, and non-compliance
with CHF medications [4]. However, each such episode of worsening
CHF that usually requires hospitalization is associated with innate
mechanisms of the development and deterioration of cardiovascular
remodeling [5]. This phenomenon of mutual interrelationship of
worsening CHF and cardiovascular remodeling due to other
exacerbating factors is described as a ‘‘pathologic circle’’ [6]. Several
biological factors that are independent predictors of morbidity and
mortality in patients with advanced CHF have been found [7,8].
Indeed, changes in brain natriuretic peptide (BNP) levels during
treatment of acutely decompensated CHF were strongly associated
with early readmission and mortality in the short-term perspective
[3,9].Serial measurementsofBNP, high-sensitivityC-reactiveprotein
(hs-CRP), and cardiac-speciﬁc troponin in circulation among patients
with CHF after discharge from hospital with the aim to assay the risk
of acute or acutely decompensated myocardial dysfunction have
been widely discussed [3,10,11]. Data on biological variation of BNP,
hs-CRP and troponin I show the differences in results and
individuality expected in CHF patients, suggesting that serial
measurements need to be undoubtedly interpreted carefully
[12,13]. All these initiate searching new biomarkers that have higher
predictive value for CHF progression in the post-discharge period
among surviving subjects with ADHF after achieving clinical
stabilization.
It is now well established that a deterioration of vascular
integrity and endothelial function, angiogenesis, coagulation, and
inﬂammation represents a crucial event in the development of CHF
[14,15]. Recent studies suggested that circulating level of both
endothelial-derived apoptotic microparticles (EMPs) [16] and
mononuclear progenitor cells (MPCs) with proangiogenic capaci-
ties are key players in the pathogenesis of cardiac failure [17].
EMPs are a heterogeneous population of submicronic vesicles that
are released in response to cell activation or apoptosis [18]. MPCs
ensure reparative processes including endothelialization of
vascular lesion fragments, as well as remodeling of extracellular
matrix and neovascularization [19]. MPCs, which co-expressed
CD34+ antigen and VEGFR-2+ vascular growth ligands (vascular
endothelial growth factor receptor-2), CD133+, CD14+, and Tie2+
(tyrosine kinase ligand), were tested as predictors of nature
evolution of ischemic CHF [17]. We previously reported about
perspective-in-use of new biomarker represented EMPs to MPCs
ratio in subjects with stable mild-to-moderate CHF [20]. The
objective of the study was to examine prognostic value of
circulating EMPs to MPCs ratio for post-discharge patients with
clinical stabilization after ischemic acutely decompensated CHF.
Methods
We consecutively enrolled 136 patients (both sexes, 62 male)
with CAD admitted with a primary diagnosis of ADHF in the
hospital between February 2010 and November 2012. All the
patients gave their voluntary written informed consent for
participation in the study. At baseline all enrolled patients were
hemodynamically stable and they had NYHA III/IV classes of
ischemic CHF. The observation period started at discharge from the
hospital and was up to 3 years. We checked all deaths, including
CHF-related death, sudden death, and all cases of repeat
hospitalizations, including cases such as worsening CHF. Dyslipi-
demia, hypertension, and type 2 diabetes mellitus were deﬁned
according to contemporary clinical guidelines [21–23].
Methods for visualization of coronary arteries
Multispiral computed tomography angiography and/or angio-
graphic studies have been carried out to verify the ischemic natureof the disease in patients. Multispiral computed tomography
angiography was carried out for all the patients prior to their
inclusion in the study after clinical stabilization and prior
discharge from the hospital. When atherosclerotic lesions of the
coronary arteries were veriﬁed, patients were subjected to
conventional angiographic examination provided indications for
revascularization were available. CAD was considered to be
diagnosed upon availability of previous angiographic examina-
tions carried out not later than 6 months previously provided no
new cardiovascular events occurred during this period, and the
procedures were available for assay. The coronary artery wall
structure was measured by means of contrast spiral computed
tomography angiography [24] on Somatom Volum Zoom scanner
(Siemens, Erlangen, Germany) with two detector rows when the
patients were holding their breath at the end of inspiration. After
preliminary native scanning, non-ionic contrast Omnipak (Amer-
sham Health, Carrigtwohill, Ireland) was administered for the
optimal image of the coronary arteries. To reconstruct the image,
0.6-mm-width axial tomographic slices were used.
Transthoracic echocardiographic examination
Transthoracic echocardiographic examination was performed
accordingtoaconventionalprocedureonallpatientsusinganAcuson
Sequola scanner (Siemens) in B-mode regimen and tissue Doppler
echocardiography regimen from parasternal, subcostal, and apical
positions over the short and long axes with a transducer with 5-mHz
frequency along with electrocardiographic monitoring. Examination
was performed by ﬁnding convenient echocardiographic windows
when the patient was in the decubitus position or lying on their left
side. Left ventricular end-diastolic and end-systolic volumes were
measured by modiﬁed Simpson’s method. Left ventricular ejection
fraction (LVEF) was assessed in compliance with the requirements of
American Society of Echocardiography [25]. Doppler velocity curves
were recorded at a horizontal sweep speed of 100 mm/s while
the patients held their breath after exhalation. An average of
3 consecutive cycles was used for the analysis. Tissue Doppler
echocardiography was carried out in 4-chamber view in each of 16
segments of the left ventricle and in 4 spots of the mitral annulus [26].
Peak systolic mitral annular (Sm), early diastolic (Em), and late
diastolic (Am) myocardial velocities were measured with the sample
volume placed at the junction of the LV wall and the mitral annulus of
the septalandlateral myocardial segments fromthe 4-chamber view,
followed by calculating velocity of early diastolic left ventricular
ﬁlling (E) to Am (E/Am) ratio and to Em (E/Em) ratio.
Calculation of glomerular ﬁltration rate
Calculation of glomerular ﬁltration rate (GFR) was carried out
using MDRD-6 formula [27].
Measurement of NT-pro-BNP, hs-C-reactive protein, total cholesterol,
and its fractions
Blood samples were taken from all patients from the
antecubital vein for the measurement of N-terminal pro-brain
natriuretic peptide (NT-pro-BNP), total cholesterol (TC) and
cholesterol fractions, and hs-C-reactive protein. Blood samples
taken in the morning (at 07.00–08.00 h) were drawn into cooled
silicone test tubes. Samples were processed according to the
recommendations of the manufacturer of the analytical technique
used. They were centrifuged upon permanent cooling at 6000 rpm
for 3 min. Then, plasma was refrigerated immediately to be stored
at a temperature not higher than 35 8C.
Circulating NT-pro-BNP level was measured at admission and
at discharge of the patients. Assessment was performed by
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tems (Minneapolis, MN, USA) commercial kits on Elecsys 1010
analyzer (Roche, Mannheim, Germany).
The hs-CRP levels were measured by using nephelometric
technique on AU640 analyzer manufactured by Diagnostic
Systems Group (Kobe, Japan).
Concentrations of TC and cholesterol of high-density lipopro-
teins (HDLP) were measured by fermentation method. Concentra-
tion of cholesterol of low-density lipoproteins (LDL-C) was
calculated according to the Friedewald formula (1972).
Assay of circulating CD31+/Annexin V+ endothelial-derived apoptotic
microparticles
Circulating EMPs were isolated from 5 mL of venous citrated
blood drawn from the ﬁstula-free arm. Platelet-free plasma (PFP)
was separated from whole blood and then was centrifuged at
20,500  rpm for 30 min. EMP pellets were washed with
Dulbecco’s minimal essential medium (supplemented with
10 mg/mL polymyxin B, 100 UI of streptomycin, and 100 U/mL
penicillin) and centrifuged again (20,500 rpm for 30 min). The
obtained supernatant was extracted, and pellets were resuspended
into the remaining 200 mL of supernatant. PFP, EMPs, pellet, and
supernatant were diluted 5-, 10-, and 5-fold in PBS, respectively.
Endothelial-derived apoptotic microparticles were phenotyped by
ﬂow cytoﬂuorimetry by phycoerythrin (PE)-conjugated monoclo-
nal antibody against CD31 (BD Biosciences, Franklin Lakes, NJ, USA)
followed by incubation with ﬂuorescein isothiocyanate (FITC)-
conjugated Annexin V (BD Biosciences) per high-deﬁnition ﬂuores-
cence activated cell sorter (HD-FACS) methodology independently
after supernatant was diluted without freezing [28]. The samples
were incubated in the dark for 15 min at room temperature
according to the manufacturer’s instructions. The samples were then
analyzed on a FC500 ﬂow cytometer (Beckman Coulter, Brea, CA,
USA) after 400 L annexin-V binding buffer was added. For each
sample, 500,000 events were analyzed. EMPs gate was deﬁned
by size, using 0.8 and 1.0 mm beads (Sigma, St. Louis, MO, USA).
CD31+/Annexin V+ microparticles were deﬁned as EMPs positively
labeled for CD31 and Annexin V (CD31+/Annexin V+) [29].
Identifying fractions of mononuclear and endothelial progenitor cells
Mononuclear cell populations were phenotyped by ﬂow
cytoﬂuorimetry by means of monoclonal antibodies labeled with
ﬂuorescein isothiocyanate (FITC) ﬂuorochromes or double-labeled
with FITC/phycoerythrin (PE) (BD Biosciences) to CD45, CD34,
CD14, Tie-2, and CD309 (VEGFR2) antigens as per HD-FACS
methodology, with red blood cells removed obligatory with lysing
buffer according to gating strategy of International Society of
Hematotherapy and Graft Engineering sequential (ISHAGE proto-
col of gating strategy) [30]. For each sample, 500,000 events were
analyzed. Circulating MPCs have been identiﬁed as CD45CD34+
cells. Proangiogenic phenotype for endothelial MPCs was deter-
mined as CD14+CD309 (VEGFR2)+Tie-2+ antigens. All data were
obtained when laser beam was scattered in longitudinal and
transversal directions in the ﬂow cytoﬂuorimeter, and the
scattergram results were analyzed by using Boolean principles
for double or triple positive events.
Statistical analysis
Statistical analysis of the obtained results was carried out in
SPSS system for Windows, Version 22 (SPSS Inc., Chicago, IL, USA).
The data were presented as mean (M) and standard deviation
(SD) or 95% conﬁdence interval (CI), as well as median (Me) and
interquartile range (IQR). To compare the main parameters ofpatients’ groups (subject to the type of distribution of the parameters
analyzed), one-tailed Student t-test or Shapiro–Wilk U-test was used.
To compare categorical variables between groups, Chi2 test (x2) and
Fisher F exact test were used. The circulating EMPs, MPCs, and NT-
pro-BNP level in the blood failed to have a normal distribution, while
distribution of the hs-CRP, TC, and cholesterol fractions had a normal
character (estimated by means of Kolmogorov–Smirnov test) and was
not subjected to any mathematical transformation. The factors that
could be associated potentially with EMP to MPC ratio were
determined by logistic regression analysis. Predictors of MPCs
declining in CHF subjects were examined in stepwise logistic
regression. C-statistics, integrated discrimination indices (IDI), and
net-reclassiﬁcation improvement (NRI) were utilized for prediction
performance analyses. Odds ratio (OR) and 95% conﬁdence interval
(95% CI) were calculated for all the independent predictors of survival
of the patients. A calculated difference of p < 0.05 was considered
signiﬁcant.
Results
Study patient population
Our study consisted of 136 patients with CAD who were
admitted to the hospital with ADHF and had stable severe chronic
cardiac failure (NYHA-III/IV) at discharge. All the subjects were
divided into two cohorts depending on whether a fatal event
occurred within the 3-year post-discharge observation period.
Median follow-up was 2.12 years. Twenty-three participants died
and CHF-related death occurred in 18 (78.3%) patients. Three
subjects (13.0%) died suddenly and two patients (8.7%) died due to
myocardial infarction. No other causes of death were deﬁned.
Additionally, 86 subjects were hospitalized repetitively due to
worsening CHF [17 cases in the dead cohort (73.9%) and 68 cases
(66.0%) in the survivors cohort]. Patient demographic character-
istics are summarized in Table 1.
As one can see from Table 1, no substantial age and gender
differences were found among persons who died and survived, as
well as differences in body mass index (BMI), GFR, glycated
hemoglobin (HbA1c), fasting blood glucose level, blood creatinine
level, TC, LDL-C, HDL-C, hs-CRP, and number of coronary vessels
damaged. No difference was found between the two cohorts in
systemic ofﬁce systolic and diastolic blood pressure (BP) and heart
rate (HR). Documented incidence of type 2 diabetes mellitus in
patients of the two cohorts was 34.9% and 39.8% (p = 0.28),
respectively. Proportions of the patients in both cohorts with other
cardiovascular risk factors, such as hypertension and dyslipidemia,
were similar. Note that there appeared no statistically signiﬁcant
change in global LVEF or diastolic performances (E/Am and E/Em)
between the two cohorts. At the same time, the level of circulating
NT-pro-BNP was statistically signiﬁcantly higher in patients who
died than in those who survived. Increased NT-pro-BNP > 30% in
circulation within hospitalization period was found in 65.2% and
59.2% in both patient cohorts (p = 0.042). When analyzing details of
pharmacotherapy, no substantial differences apart from levosi-
mendan and antiplatelets were found between the two cohorts
with regard to administration of the majority of drugs. Inotropic
support with levosimendan use was provided in 13.0% and 6.7%
cases in both patient cohorts (p = 0.026).
Circulating EMPs and MPCs level in survivors and dead patients
Medians of circulating levels of EMPs in both patient cohorts
(survivors and dead subjects) were 0.286 n/mL (95% CI = 0.271–
0.309 n/mL) and 0.673 n/mL (95% CI = 0.65–0.74 n/mL) (p < 0.001).
The data shown that EMPs number in plasma was directly related
to NYHA class of CHF (r = 0.514, p = 0.001), NT-pro-BNP (r = 0.416,
Table 1
General characteristic of patient population at discharge from the hospital.
Variable Died subjects Survived subjects p-value
n = 23 n = 103
Age, years 56.90  6.33 58.10  7.15 0.66
Males, n (%) 13 (56.5%) 49 (47.6%) 0.42
Hypertension, n (%) 12 (52.2%) 51 (45.5%) 0.47
Dyslipidemia, n (%) 10 (43.5%) 47 (45.6%) 0.62
T2DM, n (%) 8 (34.9%) 41 (39.8%) 0.28
Smoking, n (%) 7 (30.4%) 27 (26.2%) 0.22
NYHA III class, n (%) 17 (73.9%) 73 (70.9%) 0.54
NYHA IV class, n (%) 6 (26.1%) 30 (29.1%) 0.56
BMI, kg/m2 23.2 (95% CI = 22.2–26.9) 24.5 (95% CI = 21.3–27.2) 0.52
eGFR, mL/min/1.73 m2 90.5 (95% CI = 79.9–108.3) 94.7 (95% CI = 75.1–110.3) 0.61
HbA1c, % 6.5 (95% CI = 4.3–8.5) 6.9 (95% CI = 4.2–8.9) 0.66
Fasting blood glucose, mmol/L 4.64 (95% CI = 3.9–8.1) 5.20 (95% CI = 3.8–9.0) 0.72
Creatinine, mmol/L 92.5 (95% CI = 79.1–113.1) 89.2 (95% CI = 78.5–110.5) 0.56
TC, mmol/L 5.3 (95% CI = 4.6–6.0) 5.0 (95% CI = 4.2–5.8) 0.48
LDL-C, mmol/L 3.60 (95% CI = 3.20–4.18) 3.02 (95% CI = 2.80–3.90) 0.46
HDL-C, mmol/L 0.94 (95% CI = 0.92–1.06) 0.88 (95% CI = 0.82–0.97) 0.48
hs-CRP, mg/L 7.31 (95% CI = 4.60–11.72) 6.97 (95% CI = 4.15–10.85) 0.52
NT-pro-BNP, pg/mL 2237.1 (95% CI 1044.5–3590.1) 1536.3 (95% CI 1004.8–2170.5) 0.001
Increased NT-pro-BNP > 30% within 24–48 h of
hospitalization period, n (%)
15 (65.2%) 61 (59.2%) 0.042
EMPs, n/mL 0.673 (95% CI = 0.65–0.74) 0.286 (95% CI = 0.271–0.309) 0.001
MPCs, n/mL 0.12 (95% CI = 0.098–0.14) 0.28 (95% CI = 0.26–0.30) 0.001
EMPs to MPCs ratio 78.9 (95% CI = 53.0–116.6) 8.4 (95% CI = 7.6–9.2) 0.001
Systolic BP, mmHg 124  5 128  5 0.52
Diastolic BP, mmHg 72  4 75  5 0.56
Heart rate, beats per 1 min 78  5 76  4 0.44
LVEF, % 42.80  0.76 46.10  0.90 0.026
E/Am, U 16.6  0.94 16.5  1.20 0.44
E/Em, U 16.6  1.00 16.6  0.84 0.46
One-vessel coronary arteries lesion, n (%) 5 (21.7%) 24 (23.3%) 0.72
Two-vessel coronary arteries lesion, n (%) 8 (34.8%) 40 (38.8%) 0.75
Multivessel lesion, n (%) 10 (43.4%) 39 (37.9%) 0.68
Vasodilators i/v, n (%) 23 (100%) 100 (97.1%) 0.82
Levosimendan, n (%) 3 (13.0%) 7 (6.7%) 0.026
Loop diuretics, n (%) 23 (100%) 103 (100%) 0.88
ACEI or ARA, n (%) 23 (100%) 103 (100%) 0.88
Mineralocorticoid receptor antagonists, n (%) 15 (65.2%) 65 (63.1%) 0.76
Acetylsalicylic acid, n (%) 19 (82.6%) 97 (94.2%) 0.044
Other antiplatelets, n (%) 4 (17.4%) 6 (5.8%) 0.048
Statins, n (%) 10 (43.5%) 47 (45.6%) 0.62
Metformin, n (%) 8 (34.9%) 41 (39.8%) 0.28
Note: CI, conﬁdence interval; CAD, coronary artery disease; T2DM, type two diabetes mellitus; TC, total cholesterol; eGFR, estimated glomerular ﬁltration rate; HbA1c,
glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; BP, blood
pressure; BMI, body mass index; NYHA, New York Heart Association; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; U, unit; Em, early diastolic
myocardial velocity; Am, late diastolic myocardial velocity; E, peak velocity of early diastolic left ventricular ﬁlling; ACEI, angiotensin-converting enzyme inhibitor; ARA,
angiotensin-2 receptor antagonist; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; EMPs, endothelial-derived apoptotic microparticles; MPCs, mononuclear
progenitor cells.
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sion period (r = 0.404, p = 0.001), hs-CRP (r = 0.402, p = 0.002), type 2
diabetes mellitus (r = 0.398, p = 0.003), multi-vessel lesion of
coronary arteries (r = 0.362, p = 0.001), E/Am (r = 0.360, p = 0.001),
E/Em (r = 0.344, p = 0.001), gender (r = 0.318, p < 0.001 for males),
TC (r = 0.313, p = 0.001), and inversely to LVEF (r = 0.496, p = 0.001)
and estimated GFR (r = 0.408, p = 0.003).
Medians of circulating levels of MPCs in both patient cohorts
were 0.28 n/mL (95% CI = 0.26–0.30 n/mL) for survivors and
0.12 n/mL (95% CI = 0.098–0.14 n/mL) for subjects who died
(p = 0.001). There was a positive association of MPC count with
LVEF (r = 0.639; p = 0.001), E/Em ratio (r = 0.52; p = 0.001),
estimated GFR value (r = 0.486; p = 0.002); and a negative
association with NYHA class of CHF (r = 0.657; p = 0.001), with
type 2 diabetes mellitus (r = 0.610; p = 0.001), increased NT-pro-
BNP > 30% within 24–48 h of admission period (r = 0.51,
p = 0.001), NT-pro-BNP level (r = 0.473; p = 0.001), creatinine
(r = 0.394; p = 0.001), hs-CRP (r = 0.356, p = 0.003), LDL choles-
terol (r = 0.354; p = 0.001), and TC level (r = 0.258; p = 0.043).Calculated EMPs to MPCs ratios in survivor and dead patient
cohorts were 8.4 (95% CI = 7.6–9.2) and 78.9 (95% CI = 53.0–116.6),
respectively (p = 0.001). EMPs to MPCs ratio were directly related
to NYHA class of CHF (r = 0.62, p = 0.001), increased NT-pro-
BNP > 30% within 24–48 h of admission period (r = 0.54,
p = 0.002), NT-pro-BNP (r = 0.513, p = 0.001), hs-CRP (r = 0.411,
p = 0.003), type 2 diabetes mellitus (r = 0.398, p = 0.001), multi-
vessel lesion of coronary arteries (r = 0.392, p = 0.001), E/Am
(r = 0.387, p = 0.002), E/Em (r = 0.356, p = 0.002), gender (r = 0.396,
p < 0.001 for male), TC (r = 0.322, p = 0.001), age (r = 0.301,
p = 0.001), smoking (r = 0.287, p = 0.001), and inversely to LVEF
(r = 0.506, p = 0.001) and estimated GFR value (r = 0.502,
p = 0.001). No signiﬁcant association between the EMPs to MPCs
ratio with fasting plasma glucose, HbA1c, mean systolic and
diastolic blood pressure, and medications for both cohorts of
patients was found.
For further analysis the values of EMPs to MPCs ratio for the
entire patient population included in the study obtained by
calculation were distributed by quartiles (Q): Q1 (median = 9.7;
Fig. 1. Results of Kaplan–Meier survival analysis in four cohorts’ patients dependent on quartiles of EMPs to MPCs ratio. (A) The cumulative survival; (B) Recurrent
hospitalization; (C) CHF-related death. Note: Each quartile is enumerated as follows: 1 – quartile I; 2 – quartile II; 3 – quartile III, and 4 – quartile IV. Censored data are marked
on the curves suitable for appropriate quartile. EMP, endothelial-derived apoptotic microparticles; MPCs, mononuclear progenitor cells; CHF, chronic heart failure.
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(median = 41.4; 95% CI = 22.5–57.8); and Q4 (median = 73.0; 95%
CI = 58.9–96.6).
The predictive value of EMPs to MPCs ratio in study patient population
Using Kaplan–Meier survival analysis we found a signiﬁcantly
divergence of survival curves in patients with top quartile (Q4) of
EMPs to MPCs ratio when compared with low quartiles (Q1–Q3).
The curves’ divergence of events accumulation reached a statistical
signiﬁcance in 50 weeks of observation period (p < 0.001 for all
cases). No statistically signiﬁcant differences between survival in
patient cohorts with Q1 and Q2, as well as Q2 and Q3 EMPs to MPCs
ratio were found. The divergence between the two patient cohorts
with Q1 and Q3 EMPs to MPCs ratio reached signiﬁcance at the endof the study. These ﬁndings were similar for cumulative survival
(Fig. 1A), for recurrent hospitalization (Fig. 1B), and for CHF-related
death (Fig. 1C).
Multivariate logistic regression was used to assess whether any
combination of assays was able to better discriminate between
surviving and dead patients. In the logistic regression analysis, the
main factors independently related with cumulative mortality and
CHF-related rehospitalization were EPMs, MPCs, EPMs to MPCs
ratio, NT-pro-BNP, increased NT-pro-BNP > 30% within 24–48 h of
admission period, NYHA class of CHF at discharge, and LVEF.
However, EPMs to MPCs ratio had independent predictive potential
for all-cause mortality (OR = 1.62; 95% CI = 1.44–1.88; p = 0.001),
CHF-related death (OR = 1.34; 95% CI = 1.22–1.50; p = 0.002), and
also CHF-related rehospitalization (OR = 1.30; 95% CI = 1.12–1.52;
p = 0.001) when compared with other variables (Table 2).
Table 2
Independent variables for three-year all-cause mortality, CHF-related death, and CHF-related rehospitalization.
Variables All-cause mortality CHF-related death CHF-related re-hospitalization
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
EMPs at discharge 1.58 1.20–1.88 0.001 1.22 1.12–1.36 0.001 1.20 1.11–1.32 0.001
MPCs at discharge 1.21 1.06–1.43 0.002 1.15 1.03–1.28 0.001 1.06 1.02–1.09 0.001
EMPs/MPCs ratio at discharge 1.62 1.44–1.88 0.001 1.34 1.22–1.50 0.002 1.30 1.12–1.52 0.001
NYHA class of CHF at discharge 1.12 1.01–1.24 0.05 1.18 1.05–1.30 0.001 1.12 1.07–1.22 0.001
NT-pro-BNP at discharge 1.09 1.02–1.16 0.002 1.42 1.22–1.73 0.006 1.44 1.28–1.67 0.002
Increased NT-pro-BNP > 30% within admission period 1.12 1.06–1.18 0.003 1.18 1.03–2.40 0.002 1.16 1.10–1.22 0.002
LVEF 1.08 0.92–1.13 0.048 1.06 0.98–1.11 0.044 1.07 1.02–1.11 0.032
hs-CRP 1.06 1.02–1.09 0.012 1.10 0.92–1.26 0.003 1.04 0.88–1.16 0.002
CHF, chronic heart failure; OR, odds ratio; CI, conﬁdence interval; EMPs, endothelial-derived apoptotic microparticles; MPCs, mononuclear progenitor cells; NYHA,
New York Heart Association; LVEF, left ventricular ejection fraction; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; hs-CRP, high-sensitivity C-reactive protein.
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increased NT-pro-BNP > 30% within admission period remained
statistically signiﬁcant for all categories of clinical events: all-
cause mortality, CHF-related death, and CHF-related rehospitali-
zation, whereas LVEF and hs-CRP for all variables did not. Using a
stepwise model selection method for multivariable prediction
model we investigated the summary effect of any combinations of
EPMs to MPCs ratio, NT-pro-BNP, increased NT-pro-BNP > 30%
within 24–48 h of admission period on all-cause mortality, CHF-
related death, and CHF-related rehospitalization (Table 3). A
stepwise model selection method demonstrated that NT-pro-BNP
at discharge, increased NT-proBNP > 30% within 24–48 h of
admission period, NYHA class of CHF at discharge, LVEF, hs-CRP
added to EPMs to MPCs ratio do not offer additional discriminatory
potential.
Using reclassiﬁcation methods, however, we found that the
addition of EPMs to MPCs ratio to the ABC model (NT-pro-BNP,
increased NT-pro-BNP > 30%) improved the relative IDI by 19.6%
for all-cause mortality, by 21.7% for CHF-related death, and by
19.5% for CHF-related rehospitalization (Table 4). For category-free
NRI, 14% of events (p = 0.001) and 23% of non-events (p = 0.0001)
were correctly reclassiﬁed by the addition of EPMs to MPCs ratio to
the ABC model for all-cause mortality (Table 5). When EPMs to
MPCs ratio was added to the ABC model, 15% of events (p = 0.001)Table 3
Predictive value of EPMs to MPCs ratio for combined end-point (all-cause mortality a
additional information to discriminate between survivors and dead patients with ischem
were added to predicted model based on EPMs to MPCs ratio.
Prognostic model 
Model 6 
Model 5 
Model 4 
Model 3 
Model 2 
0.8 1.0 1.2 1.4 1.6 1.8 2.0
Model 1
Model 2
Model 3
Model 4
Model 5
Model 6
Odds ratio Model 1 
Notes: Model 1: EPMs to MPCs ratio; Model 2: EPMs to MPCs ratio + NT-pro-BNP at disc
within admission period; Model 4: EPMs to MPCs ratio + NT-pro-BNP + increased NT-pr
EPMs to MPCs ratio + NT-pro-BNP + increased NT-pro-BNP > 30% within admission perio
BNP + increased NT-pro-BNP > 30% within admission period + NYHA class of CHF at d
EMPs, endothelial-derived apoptotic microparticles; MPCs, mononuclear progenitor cel
pro-BNP, N-terminal pro-brain natriuretic peptide; hs-CRP, high-sensitivity C-reactivand 29% of non-events (p = 0.002) were reclassiﬁed for CHF-related
death. Therefore, 13% of events (p = 0.001) and 22% of non-events
(p = 0.002) were reclassiﬁed for CHF-related rehospitalization.
Thus, we suggest that EPMs to MPCs ratio remained a statistically
signiﬁcant predictor for combined end-point including all-cause
mortality and CHF-related readmission.
Discussion
Well known that levels of circulating microparticles are
enhanced in a large number of pathological states including
cardiovascular diseases, such as CHF and metabolic disorders, and
this has been linked to deleterious effects on cells from the vascular
wall, mainly, endothelial cells. Circulating microparticles have
been considered as biomarkers as well as potential mediators of
biological messages between different type cells. Endothelial
microparticles are complex vesicular structures that originate from
plasma membranes of activated or apoptotic endothelial cells [31].
While endothelial-derived apoptotic microparticles could com-
promise vascular homeostasis and then represent key players in
the pathogenesis of several inﬂammatory and thrombotic diseases,
their role in cardiovascular diseases is not understood. Circulating
EMPs are increased in CAD, hypertension, atrial ﬁbrillation,
peripheral vascular disease, and also CHF [32–34]. However, theynd CHF-related rehospitalization). Multivariable prediction model shows lack of
ic severe CHF when NT-proBNP, NYHA class of CHF at discharge, LVEF, and hs-CRP
95% CI OR p-value 
0.001 1.08–1.66 1.41 
0.002 1.03–1.67 1.44 
0.001 1.05–1.72 1.47 
0.003 1.08–1.63 1.45 
0.001 1.09–1.77 1.46 
0.001 1.18–1.76 1.53 
harge; Model 3: EPMs to MPCs ratio + NT-pro-BNP + increased NT-pro-BNP > 30%
o-BNP > 30% within admission period + NYHA class of CHF at discharge; Model 5:
d + NYHA class of CHF at discharge + LVEF; Model 6: EPMs to MPCs ratio + NT-pro-
ischarge + LVEF + hs-CRP.
ls; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; NT-
e protein.
Table 4
C-statistics for models with EPMs to MPCs ratio, NT-pro-BNP, increased NT-pro-BNP > 30% within 24–48 h of admission period as continuous variables.
Models AUC (95% CI) DAUC IDI (SE) Relative IDI (%)
All-cause mortality
Model 1 (NT-pro-BNP, increased NT-pro-BNP > 30%) 0.683 – – –
Model 1 + EPMs to MPCs ratio 0.834 – – –
Model 1 + EPMs to MPCs ratio vs Model 1 – 0.151; p = 0.001 0.03  0.011 19.6%
CHF-related death
Model 1 (NT-pro-BNP, increased NT-pro-BNP > 30%) 0.646 – – –
Model 1 + EPMs to MPCs ratio 0.872 – – –
Model 1 + EPMs to MPCs ratio vs Model 1 – 0.226; p = 0.0001 0.07  0.015 21.7%
CHF-related rehospitalization
Model 1 (NT-pro-BNP, increased NT-pro-BNP > 30%) 0.657 – – –
Model 1 + EPMs to MPCs ratio 0.854 – – –
Model 1 + EPMs to MPCs ratio vs Model 1 – 0.197; p = 0.0012 0.06  0.012 19.5%
Note: Relative IDI – calculated as the ratio of IDI over the discrimination slope of the model without EPMs to MPCs ratio.
AUC, area under the curve; SE, standard error; IDI, integrated discrimination index; MPCs, mononuclear progenitor cells; EMPs, endothelial-derived apoptotic
microparticles; NT-pro-BNP, N-terminal pro-brain natriuretic peptide.
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proposed to be a potent marker of ischemic risk. Sinning et al.
[35] reported that the level of circulating EMPs with apoptotic
phenotype CD31+/Annexin V+ is an independent predictor of
cardiovascular events in stable CAD patients and may be useful for
risk stratiﬁcation. Moreover, EMPs may contribute inﬂammatory,
thrombogenic, and proteolytic pathways that are suitable for acute
and acutely decompensated CHF [19]. The main advantage of this
biomarker is the lack of tight interrelationship between numerous
of EMPs in blood and creatinine clearance, GFR, and sex that is a
notably important issue in acutely decompensated CHF patients.
Mononuclear progenitor cells are mobilized into circulation to
replace damaged endothelium and recapitulate the vascular
network of injured tissues. Numerous studies have reported that
MPCs with proangiogenic phenotype CD14+CD309(VEGFR2)+Tie-
2+ play an important role in vascular repair and restoration of
endothelial function [19,36,37]. Therefore, signiﬁcant variability in
the degree of change in EMPs and MPCs levels between individualsTable 5
Prediction performance analyses for models with EPMs to MPCs ratio, NT-pro-BNP,
increased NT-pro-BNP > 30% within 24–48 h of admission period as continuous
variables.
Model 2 vs model 1
All-cause mortality
Categorical NRI 0.13 (95% CI 0.09–0.17)
Percentage of events correctly reclassiﬁed 7 (p = 0.12)
Percentage of non-events correctly reclassiﬁed 9 (p = 0.023)
Categorical free NRI 0.57 (95% CI 0.44–0.69)
Percentage of events correctly reclassiﬁed 14% (p = 0.001)
Percentage of non-events correctly reclassiﬁed 23% (p = 0.0001)
CHF-related death
Categorical NRI 0.15 (95% CI 0.12–0.17)
Percentage of events correctly reclassiﬁed 4 (p = 0.11)
Percentage of non-events correctly reclassiﬁed 7 (p = 0.012)
Categorical free NRI 0.42 (95% CI 0.31–0.57)
Percentage of events correctly reclassiﬁed 15% (p = 0.001)
Percentage of non-events correctly reclassiﬁed 29% (p = 0.002)
CHF-related rehospitalization
Categorical NRI 0.11 (95% CI 0.06–0.19)
Percentage of events correctly reclassiﬁed 5 (p = 0.16)
Percentage of non-events correctly reclassiﬁed 5 (p = 0.018)
Categorical free NRI 0.37 (95% CI 0.30–0.43)
Percentage of events correctly reclassiﬁed 13% (p = 0.001)
Percentage of non-events correctly reclassiﬁed 22% (p = 0.001)
Note: Model 1 – NT-pro-BNP, increased NT-pro-BNP > 30%; Model 2 – NT-pro-
BNP, increased NT-pro-BNP > 30% and EPMs to MPCs ratio.
NRI, net reclassiﬁcation improvement; MPCs, mononuclear progenitor cells;
EMPs, endothelial-derived apoptotic microparticles; NT-pro-BNP, N-terminal
pro-brain natriuretic peptide; CHF, chronic heart failure.with ischemic CHF raises the interesting possibility that they could
be a predictive biomarker in this patient population [38]. We
previously reported that a decreased circulating level of
CD14+CD309+Tei2+ MPCs is related to a number of cardiovascular
risk factors in patients with known CAD and CHF [17,39]. Alba et al.
[37] found that a decrease in CD34+VEGFR2+ cells was indepen-
dently associated with functional capacity of CHF patients and
increased mortality. However, predictive potential of both CD31+/
Annexin V+ EMPs and CD14+CD309(VEGFR2)+Tie-2+ MPCs when
compared with brain natriuretic peptides and hs-CRP is still not
clear.
It has been postulated that imbalance between exaggerated
production of EMPs and deﬁciency of MPCs with proangiogenic
potency in circulation may characterize an insufﬁciency in tissue
repair response more closely than each biomarker alone.
Moreover, using EMP to MPC ratio may also lead to minimize
bias related to age-dependent disease, metabolic disorders, and
demographic particularities. We suggest that CD31+/Annexin V+
EMPs to CD14+CD309(VEGFR2)+Tie-2+ MPCs ratio may reﬂect an
imbalance between vascular repair and endothelial dysfunction
that is suitable for worsening CHF. Probably, predictive value of
EMPs to MPCs ratio will not be worse than circulating NT-proBNP,
hs-CRP, and serial measurements of NT-proBNP plasma level in
subjects with worsening CHF or ADHF. Indeed, we found that EPMs
to MPCs ratio had an independent prognostic potential for all-
cause mortality, CHF-related death, and also CHF-related rehospi-
talization and that calculated predictive value was superior when
compared with EPMs at discharge alone, MPCs at discharge alone,
NT-pro-BNP at discharge, increased NT-pro-BNP > 30% within 24–
48 h of admission period, NYHA class of CHF at discharge, or LVEF
at discharge. In multivariable prediction model the summary effect
of any combinations of EPMs to MPCs ratio with other variables
(NT-pro-BNP, increased NT-pro-BNP > 30% within 24–48 h of
admission period) on combined end-point point (all-cause
mortality and CHF-related rehospitalization) was not superior to
EPMs to MPCs ratio alone. Recent data support the hypothesis that
EMPs and MPCs contribute to vascular homoeostasis and the
pathogenesis of CHF, including mechanisms of worsening endo-
thelial dysfunction [40,41]. We agree with several investigators in
terms that the disproportion in circulating levels of both EMPs and
MPCs may trigger differential consequences on cardiovascular
remodeling [35,40,41]. Although results of recent studies dedicat-
ed to investigation of EPCs and MPCs in CHF were inconsistent and
suggested that levels of both biomarkers may vary according to
factors such as disease severity, underlying cause of cardiomyop-
athy and medical therapy, we believe that EPCs to MPCs ratio use
as a prognostic marker may diminish this controversy [42]. New
A.E. Berezin et al. / Journal of Cardiology 65 (2015) 403–411410studies with more size and statistical power and clinical follow-up
are required to determine the prognostic signiﬁcance of these
ﬁndings.
Study limitations
This study has some limitations. The major limitation of this
study was the small population size. However, this was not a
randomized and controlled study. The authors suggested that a
greater cohort of patients with more incidences detected is
desirable to improve the credibility of the study. It is necessary to
note that a large pool of nanoparticles might be produced after
blood sampling due to destruction of platelets and blood cells.
Therefore, preparation of isolates of microparticles in samples is
the most sophisticated step for further examination. Venous
citrated blood drawn from the ﬁstula-free arm was performed
obligatorily. We believe that these risks are systemic, and to
minimize them, we refused to freeze the blood samples before
measurement of microparticles. Although HD-FACS methodology
is widely used, theoretically overlap between two or more
ﬂuorochromes might reﬂect some obstacles for further interpre-
tation of obtained results. Another limitation of the present study
is that a speciﬁc role of EMPs and PMCs is also possible and has not
been characterized in depth in CHF patients. However, the authors
suppose that these restrictions might have no signiﬁcant impact on
the study data interpretation.
Conclusion
We demonstrated that EMPs to MPCs ratio is considered a more
important indicator of an imbalance between angiogenic and
apoptotic responses with possible relation to cardiovascular
outcomes in post-discharge patients with clinical stabilization
after ischemic ADHF. The fourth quartile of EMPs to MPCs ratio
shows a close association with increased three-year CHF-related
death, all-cause mortality, and risk for recurrent admission due to
worsening CHF after discharge from the hospital.
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